Why Mereo BioPharma Group plc’s (MREO) Stock Is Down 5.61%
As of Monday, August 17, Mereo BioPharma Group plc’s MREO share price has dipped by 5.61%, which has investors questioning if this is right time to buy.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of rare diseases in the United Kingdom and the United States. The company develops Setrusumab, an antibody for the treatment of osteogenesis imperfecta; Alvelestat, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency associated lung disease; and Vantictumab, an anti-FZD monoclonal antibody for the treatment of autosomal dominant osteopetrosis type 2. It also develops Leflutrozole, an oral aromatase inhibitor, which is in Phase 2 trials for use in the treatment of hypogonadotropic hypogonadism; Navicixizumab, which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Etigilimab, an IgG1 monoclonal antibody which binds to the human TIGIT receptor on immune cells for the Treatment of advanced solid tumors; and Acumapimod, a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; and licensing agreement with AstraZeneca. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, United Kingdom.
Commentary & Analysis
Why Mereo BioPharma Group plc’s (MREO) Stock Is Up 5.75%
As of Friday, July 31, Mereo BioPharma Group plc’s MREO share price has surged by 5.75%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Mereo BioPharma Group plc’s (MREO) Stock Is Down 5.98%
As of Wednesday, July 08, Mereo BioPharma Group plc’s MREO share price has dipped by 5.98%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Mereo BioPharma Group plc’s (MREO) Stock Is Down 6.95%
As of Wednesday, May 27, Mereo BioPharma Group plc’s MREO share price has dipped by 6.95%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Mereo BioPharma Group plc’s (MREO) Stock Is Down 5.02%
As of Wednesday, April 15, Mereo BioPharma Group plc’s MREO share price has dipped by 5.02%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Financial Summary
| Share Statistics | MREO | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $42.7 | $288.9 | 14% |
|
| Shares Out (Mil) | 160.7 | 54.0 | 72% |
|
| Institutional Ownership | 94.3% | 93.1% | 65% |
|
| Float (Mil) | 130.8 | 41.4 | 66% |
|
| Beta | 0.30 | 0.94 | 18% |
|
| Avg Daily Volume (000s) | 1,110 | 480 | 74% |
|
| Price Change (52-week) |
(84.9%) | 59.9% | 6% |
|
| Growth | MREO | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 14.1% | na |
|
| Net Income (5yr) | 28.4% | (10.1%) | 83% |
|
| EPS (5yr) | 39.7% | 15.9% | 88 |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | (29.5%) | (15.6%) | 20% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 6 | 6 | 6 | |
| Current EPS | ($0.015) | ($0.056) | ($0.023) | |
| Month Ago EPS | ($0.009) | ($0.038) | ($0.034) | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | ($0.009) | ($0.038) | ($0.038) | |
| Year/Year Chg | (65.9%) | (78.7%) | (73.0%) | |
| Financials | MREO | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($28) | ($43) | 21% |
|
| EPS (TTM) | ($0.175) | ($1.500) | 34% |
|
| Operating Cash Flow (TTM) (Mil) | ($25) | ($31) | 13% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | $21 | $190 | 11% |
|
| Valuation | MREO | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.48 | 2.84 | 38% |
|
| P/E | na | 20.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | MREO | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.9% | na |
|
| Net Margin | na | (74.2%) | na |
|
| ROA | (57.7%) | (47.7%) | 10% |
|
| ROE | (67.8%) | (55.0%) | 12% |
|
| Liabilities to Assets | 17.5% | 29.6% | 11% |
|
| F-Score | 2 | 3 | 7% |
|
Mereo BioPharma Group plc did not pass any screens on 9/2/2026.
